Recon Strategy
Contact

Insights

Fifteen+ years of
healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

ESSENTIAL READING

  • Biopharma, Payers, Institutional

Outcomes Based Arrangements in Biopharma

Today’s advanced therapies target devastating diseases with high unmet need. Given the urgent medical need (and pressure from patient advocates), regulators increasingly must make decisions based on early, incomplete data when it comes to durability, real-world effectiveness, and cost-effectiveness – all while bearing costs that can exceed $1 million per patient.
  • Biopharma

A few thoughts about navigating biopharma macro scenarios

Planning biopharma strategies against a robust set of macro-scenarios will be crucial to mid- and long-term success. While historically these scenarios have revolved around targeted issues, the current challengescall for a more expansive - and likely more difficult - set of questions to be asked.
  • Biopharma, Payers, Providers, Medtech, Digital

Why the Best AI Won’t Win in Healthcare

As advanced AI becomes widely accessible, healthcare companies can no longer rely on superior technology alone for lasting advantage. Instead, they need a coherent AI strategy built around five interconnected choices. Harvard Business Review article.
Sector
All
NEJM opinion

NEJM Highlights March 2015: Progress against Crohn’s, PCSK9 inhibitors coming through, comparative effectiveness for diabetic macular edema, Eric Lander encourages the FDA on genomic testing regulation

  • NEJM
A promising agent for Crohn’s Disease, a miserable illness Crohn’s is …

Read more

A sizeable step forward but miles still to go: CMS’ Next Generation ACO model

  • Payers , 
  • Providers
CMS has issued a “Request for Applications” describing its Next Genera…

Read more

Biopharma innovation: Will there be sufficient incentives in the future?

  • Biopharma
Ezekiel Emanuel wrote an op-ed in the New York Times last month, which…

Read more

NEJM Highlights February 2015: the most boring month in my NEJM reading memory

  • NEJM
Our selection from a month with relatively few exciting articles - per…

Read more

NEJM Highlights January 2015: Dengue vaccine, Informed consent, Cancer drugs and Tiering for selection

  • NEJM
A vaccine for dengue finally nears the market Dengue is a mosquito tra…

Read more

Cosgrove moves south: competitive implications of the formation of the Midwest Health Collaborative

  • Providers
A few days ago, Cleveland Clinic announced the formation of the Midwes…

Read more

Shifting lines in the mobile health competitive battlefield: Aetna makes a strategic retreat while United digs in?

  • Payers , 
  • Digital
The battle to own healthcare’s consumer relationship is being nowhere …

Read more

The “weaponization” of ACO narrow networks: Strategic destabilizers which compel their own replication?

  • Payers , 
  • Providers
In theory, narrow networks built around a single provider or a network…

Read more

Ochsner and River Parishes: one type of endgame for managing redundant hospital capacity (updated)

  • Providers
Please see update at end of post. If value-based care broadly delivers…

Read more

SELECTED ENGAGEMENTS

Insight, put to work

Our published thinking is one half of the picture. These are representative client engagements, anonymized — each tagged by sector, so you can trace the path from perspective to practice.

  • Institutional

Strategy for Statewide Health Information Exchange

A non-profit health information exchange was facing financial struggles and needed a new strategy that would keep it financially sustainable

HIE, Health IT,

  • Medtech, Early Stage

Growth strategy for point-of-care testing

Post pandemic an innovative diagnostics platform company wanted to dramatically increase its market by targeting retail clinics for its point-of-care diagnostics platform

Growth, product market fit, value proposition

  • Institutional

University Trials

Large university wanting to dramatically increase its clinical research footprint

Keep up with Recon Strategy Insights
Get an email each time we publish a new article